Detection of liver metastases with 5'-nucleotide phosphodiesterase isozyme-V in gastrointestinal cancer patients.
An evaluation of the 5'-nucleotide phosphodiesterase isozyme V (5'-NPD-V) test for liver metastases in gastrointestinal (GI) cancer patients was undertaken with a coded serum panel provided by NCI Mayo Clinic. Upon decoding, 28 of 30 patients (93%) with known liver metastases and 11 or 32 patients (36%) with no known liver metastases were positive. In 20 patients with various benign GI diseases, there were 6 (30%) positive for 5'-NPD-V. 2 of these positive patients with benign GI diseases had identifiable liver disorders. Statistical analysis of the data supports 5'-NPD-V can discriminate between GI cancer patients with and without liver metastases and patients with benign GI diseases.